Thiazide-induced dysglycemia: it’s time to take notice

References

• Wolff FW, Parmley WW, White K, Okun R. Drug-induced diabetes. JAMA185, 568–574 (1963).
   Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.166, 2191–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of Type 2 diabetes in the randomized multiple risk factor intervention trial. Ann. Intern. Med.142, 313–322 (2005).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension43, 963–969 (2004).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Cooper-Dehoff RM. Cardiovascular therapies and risk for development of diabetes. J. Am. Coll. Cardiol.44, 509–512 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care31, 982–988 (2008).
   PubMed Web of Science ®Google Scholar
• Cutler JA. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key? Hypertension48, 198–200 (2006).
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Harris-Haywood S, Pressel S et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.168, 207–217 (2008).
   PubMedGoogle Scholar
• Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension50, 459–460 (2007).
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension48, 219–224 (2006).
   PubMed Web of Science ®Google Scholar
• Carter BL, Einhorn PT, Brands M et al. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension52, 30–36 (2008).
   PubMed Web of Science ®Google Scholar
• Helderman JH, Elahi D, Andersen DK et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes32, 106–111 (1983).
   PubMed Web of Science ®Google Scholar
• Cooper-Dehoff R, Cohen JD, Bakris GL et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the International Verapamil SR-Trandolapril Study [INVEST]). Am. J. Cardiol.98, 890–894 (2006).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care30(Suppl. 1), S4–S41 (2007).
   PubMedGoogle Scholar
• American Heart Association. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA288, 2709–2716 (2002).
   PubMed Web of Science ®Google Scholar
• Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation110, 1251–1257 (2004).
   PubMed Web of Science ®Google Scholar
• Black HR, Davis B, Barzilay J et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care31, 353–360 (2008).
   PubMed Web of Science ®Google Scholar
• Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA290, 1884–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens.20, 1879–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J.28, 1462–1536 (2007).
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr. Pract.12, 193–222 (2006).
   PubMedGoogle Scholar
• Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J. Renin Angiotensin Aldosterone Syst.7, 61–63 (2006).
   PubMed Web of Science ®Google Scholar